SelectScience®’s Post

MATCHMAKERS, one of three #CancerGrandChallenges teams co-funded by The Mark Foundation for Cancer Research, is taking on our T-cell receptors challenge. We recently spoke with Michael Birnbaum (MIT Koch Institute for Integrative Cancer Research, team lead of MATCHMAKERS) and Ryan Schoenfeld (CEO, The Mark Foundation for Cancer Research) about the team's ambitious approach to the challenge. Read the article 👉 https://bit.ly/3zr1iPi

🌟 Customer Success Spotlight 🌟 See how Ada Junquera and the Färkkilä Lab are transforming ovarian cancer research with GeoMx DSP! Their latest findings, now published in Cancer Cell, showcase the power of spatial molecular characterization. With plans to expand into Discovery Multiomics, their work underscores GeoMx DSP’s potential to provide integrated insights into health and disease from precious tissue samples, transforming the way we approach complex cancers like ovarian cancer. Dive into their results now 👉 https://lnkd.in/dbnUjhQg #CancerResearch #OvarianCancer #SpatialMultiomics

"Since Brexit, it was not possible for UK (based) researchers to access such large-scale grants. I think its great news that the UK has rejoined the Horizon (Europe) programme. It makes the country more attractive for international researchers such as me, especially at the early career stage." Comments from astrophysicist Clement Bonnerot, at the University of Birmingham, who will use new ERC Starting Grant funding to investigate what happens when supermassive black holes tear stars apart. Mishal Hussain of BBC radio 4, interviewed Evangelos Giampazolias and Clement Bonnerot, two recent winners of ERC Starting Grant. Evangelos Giampazolias's new research project will be based at The University of Manchester. He agreed with Hussain that he would not have been able to access this (ERC) funding before this (at least not while working from the UK). He said: "Its an incredible honour being funded by the ERC. Basically this complements my funding from Cancer Research UK, and allows me to interact with scientists across the globe." When the new batch of awardees were announced last week, ERC President Maria Leptin noted: "I am particularly pleased to welcome UK researchers back to the ERC. They have been sorely missed over the past years. With fifty grants awarded to researchers based in the UK, this influx is good for the research community overall." More on the 494 Starting Grants (worth 780 million euro) that were recently award by the European Research Council (ERC) 👉 https://lnkd.in/dg6BhxBD #EUfunded #FrontierResearch #ERCStG BBC Cancer Research UK Manchester Institute UK Research Office (UKRO) EU Science, Research and Innovation

Exciting new commentary by our Conquering KRAS in Pancreatic Cancer TeamLab members, Dr. Anirban Maitra from MD Anderson Cancer Center and Dr. Andrew J. Aguirre from Dana-Farber Cancer Institute is now published in Cancer Research, an American Association for Cancer Research journal. The commentary highlights that advancements in KRAS inhibition for pancreatic cancer are driven by strong collaborations!    “The current 'revolution' in KRAS inhibition was made possible by partnerships between oncologists and pathologists, cancer biologists and chemists, and academia and biotech—a spirit of collaboration motivated by the importance of the problem at hand."   Read more here: https://lnkd.in/epwWYw-6   #RadicalCollaboration #CancerResearch 

Every year, researchers at Memorial Sloan Kettering Cancer Center (MSK) work to advance the global understanding of cancer and develop new therapies, and 2024 was no exception. “MSK scientists continue to expand our understanding of cancer and to apply what we learn in the lab to improve the lives of patients," says MSK President and CEO Dr. Selwyn Vickers. "The discoveries that we’re making today provide the foundation for the therapies of tomorrow.” Learn about some of the most exciting scientific discoveries reported over the past year, in chronological order: https://lnkd.in/e_Q8JhuG

The poster sessions at #AACR are underway! Director of Metabolomics, Ethan Stancliffe, is presenting our work on an integrated multi-omics analysis of colorectal cancer patients. Make sure to stop by the poster area to learn more about the types of insights that can be gained for your cancer research by integrating multiple 'omics datasets. If you aren't attending the conference, download a sample data report with data from this experiment here: https://hubs.ly/Q02shHc_0

Komen researcher Kristen Brantley, Ph.D. from Dana-Farber Cancer Institute is investigating the underlying biological factors that lead to worse breast cancer outcomes and survival in young women, with hopes to find better, more personalized treatments for these patients. “Expanding our knowledge about the biology behind breast cancer is going to give us tools to improve early identification of high-risk patients,” Dr. Brantley says. Learn more here: https://bit.ly/42rO699

In a significant development, once in a lifetime, the Quad Cancer Moonshot has been officially launched today in Delaware by the global hub | United States, Australia, India, and Japan. This collaborative initiative aims to fundamentally transform the cancer care ecosystem and address the pressing need to eliminate cancer as a public health threat within the Indo-Pacific region. The initiative is projected to save hundreds of thousands of lives over the forthcoming decades. The Quad partners have consolidated their resources, expertise and innovative approaches to mount a comprehensive response to the cancer crisis, particularly addressing the existing disparities in healthcare access and treatment outcomes across the region. The overarching objective of this initiative is to ensure that advanced treatments and preventive measures are universally accessible, thereby reframing cancer from a formidable challenge into a manageable health condition. Through the Quad Cancer Moonshot, strategic collaborations in research are being established, best practices are being disseminated and community engagement is being prioritized. This framework is designed to empower individuals to take proactive steps regarding their health and well-being, while simultaneously articulating a clear vision for the future of cancer care—one that significantly mitigates the burden of this disease. As a symbol of international cooperation, the Quad underscores the importance of multilateral partnerships in addressing global health challenges. This initiative is poised to catalyze a global movement towards equitable and comprehensive cancer care, demonstrating the potential outcomes of collaborative governance among nations united by a common purpose. In light of these developments, it is imperative that stakeholders from various sectors rally behind the Quad Cancer Moonshot. By doing so, a future devoid of the overwhelming impacts of cancer can be realized, fostering an environment where health equity and hope can flourish throughout the Indo-Pacific and beyond. Empowerment of the Quad Powerhouse #QuadCancerMoonshot #CancerCare #IndoPacificHealth #GlobalHealthInitiative #HealthEquity #CancerPrevention #PublicHealth #InternationalCooperation #ResearchCollaboration #HealthcareAccess #CancerAwareness #TransformingCancerCare #QuadPartnership #HealthInnovation #EmpowermentThroughHealth #USA #Australia #India #Japan #CNN #CNNinternational #QuadLeadersSummit #QUAD

Today is World Cancer Research Day — a reminder of the critical role research plays in transforming lives. At Breast Cancer Canada, we are dedicated to driving progress, working to improve patient outcomes and save lives. Every advancement we make is made possible by science and the support from donors like you. Together, we are moving closer to a future where breast cancer is managed with the least invasive and most effective personalized treatments. Join the progress at: breastcancerprogress.ca #breastcancerresearch

Collaboration is a necessity in ensuring a relevant, vibrant, impactful research agenda 🤝 ANZGOG has a diverse, multidisciplinary membership of experts who pool their knowledge, share insights, and combine their strengths to advance gynaecological cancer research. One particular collaboration is between scientists and clinicians, who work together to advance research 'bench to bedside' for gynaecological cancer patients. Watch Professor David Bowtell, a world-leading ovarian cancer researcher and ANZGOG member, talk about the importance of this collaboration below 👇 #AdvancingResearchSavingLives